TFE3-rearranged ossifying fibromyxoid tumors are uniquely negative for glycoprotein non-metastatic melanoma protein B: A study of 13 TFE3-rearranged mesenchymal tumors

IF 2.7 2区医学 Q2 PATHOLOGY

Human pathology Pub Date : 2025-03-01 DOI:10.1016/j.humpath.2025.105768

Burak Tekin Instructor in Pathology , Andrew L. Folpe Professor of Pathology , Surendra Dasari Associate Professor of Biomedical Informatics , Christopher D. Hofich Principal Developer, Department of Lab Medicine and Pathology , Michael McCarthy Resident Physician, Pathology , Saba Alvand Visiting Research Fellow, Pathology , Ganesh P. Pujari Visiting Research Fellow, Pathology , Kevin C. Halling Professor of Pathology , John C. Cheville Professor of Pathology , Rumeal D. Whaley Assistant Professor of Pathology , Sounak Gupta Associate Professor of Laboratory Medicine and Pathology

{"title":"TFE3-rearranged ossifying fibromyxoid tumors are uniquely negative for glycoprotein non-metastatic melanoma protein B: A study of 13 TFE3-rearranged mesenchymal tumors","authors":"Burak Tekin Instructor in Pathology , Andrew L. Folpe Professor of Pathology , Surendra Dasari Associate Professor of Biomedical Informatics , Christopher D. Hofich Principal Developer, Department of Lab Medicine and Pathology , Michael McCarthy Resident Physician, Pathology , Saba Alvand Visiting Research Fellow, Pathology , Ganesh P. Pujari Visiting Research Fellow, Pathology , Kevin C. Halling Professor of Pathology , John C. Cheville Professor of Pathology , Rumeal D. Whaley Assistant Professor of Pathology , Sounak Gupta Associate Professor of Laboratory Medicine and Pathology","doi":"10.1016/j.humpath.2025.105768","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transcriptional target of <em>MiTF/TFE3</em>. Prior studies have shown that immunohistochemistry for GPNMB is a sensitive screening tool for renal cell carcinomas with alterations of <em>TSC1/TSC2/MTOR</em>, <em>TFE3</em>, and <em>TFEB</em> genes, as well as alveolar soft part sarcomas (ASPS) and perivascular epithelioid cell neoplasms (PEComas). However, GPNMB expression has not been systematically evaluated in a diverse group of molecularly confirmed, <em>TFE3</em>-rearranged mesenchymal tumors.</div></div><div><h3>Methods</h3><div>Our archive was interrogated for <em>TFE3</em>-rearranged non-renal neoplasms previously assessed with our RNA NGS panel. For each case, a whole-slide section was immunostained for GPNMB, and quantified using H-scores. The methylation profiles of the included tumor types were retrieved from our database.</div></div><div><h3>Results</h3><div>Thirteen <em>TFE3</em>-rearranged tumors were identified, including 6 ossifying fibromyxoid tumors (OFMTs) (<em>PHF1::TFE3</em>), 3 PEComas/PEComa-like neoplasms (<em>ASPSCR1::TFE3</em>, <em>DVL2::TFE3</em>, and <em>PRCC::TFE3</em>, one case each), 2 <em>YAP1::TFE3</em>-rearranged hemangioendotheliomas, one ASPS (<em>ASPSCR1::TFE3</em>), and one unclassified <em>CBX4::TFE3</em>-rearranged sarcoma. Tumors harboring <em>ASPSCR1</em>, <em>PRCC</em>, <em>YAP1</em>, and <em>DVL2</em> as the fusion partner had a mean H-score of 300, 300, 290 and 280, respectively. All 6 <em>PHF1</em>::<em>TFE3</em>-rearranged OFMTs and the <em>CBX4</em>::<em>TFE3</em>-rearranged sarcoma were GPNMB-negative, despite having similar <em>TFE3</em> breakpoints to the positive cases (exon 6–7). <em>PHF1::TFE3</em>-rearranged OFMT showed relative hypermethylation of the <em>GPNMB</em> promoter locus cg02203656 compared to ASPS (<em>p</em> = 0.027).</div></div><div><h3>Conclusions</h3><div>Although study of additional cases is necessary, these findings suggest that the downstream effects of <em>TFE3</em>-rearrangement are different in <em>PHF1::TFE3</em>-rearranged OFMTs, compared to other known <em>TFE3</em>-rearranged neoplasms. <em>TFE3</em>-rearranged OFMTs are epigenetically distinct, implying that the impact of <em>TFE3</em>-rearrangement may be lineage-dependent.</div></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"157 ","pages":"Article 105768"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0046817725000553","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transcriptional target of MiTF/TFE3. Prior studies have shown that immunohistochemistry for GPNMB is a sensitive screening tool for renal cell carcinomas with alterations of TSC1/TSC2/MTOR, TFE3, and TFEB genes, as well as alveolar soft part sarcomas (ASPS) and perivascular epithelioid cell neoplasms (PEComas). However, GPNMB expression has not been systematically evaluated in a diverse group of molecularly confirmed, TFE3-rearranged mesenchymal tumors.

Methods

Our archive was interrogated for TFE3-rearranged non-renal neoplasms previously assessed with our RNA NGS panel. For each case, a whole-slide section was immunostained for GPNMB, and quantified using H-scores. The methylation profiles of the included tumor types were retrieved from our database.

Results

Thirteen TFE3-rearranged tumors were identified, including 6 ossifying fibromyxoid tumors (OFMTs) (PHF1::TFE3), 3 PEComas/PEComa-like neoplasms (ASPSCR1::TFE3, DVL2::TFE3, and PRCC::TFE3, one case each), 2 YAP1::TFE3-rearranged hemangioendotheliomas, one ASPS (ASPSCR1::TFE3), and one unclassified CBX4::TFE3-rearranged sarcoma. Tumors harboring ASPSCR1, PRCC, YAP1, and DVL2 as the fusion partner had a mean H-score of 300, 300, 290 and 280, respectively. All 6 PHF1::TFE3-rearranged OFMTs and the CBX4::TFE3-rearranged sarcoma were GPNMB-negative, despite having similar TFE3 breakpoints to the positive cases (exon 6–7). PHF1::TFE3-rearranged OFMT showed relative hypermethylation of the GPNMB promoter locus cg02203656 compared to ASPS (p = 0.027).

Conclusions

Although study of additional cases is necessary, these findings suggest that the downstream effects of TFE3-rearrangement are different in PHF1::TFE3-rearranged OFMTs, compared to other known TFE3-rearranged neoplasms. TFE3-rearranged OFMTs are epigenetically distinct, implying that the impact of TFE3-rearrangement may be lineage-dependent.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Human pathology 医学-病理学

CiteScore

5.30

自引率

6.10%

发文量

206

审稿时长

21 days

期刊介绍： Human Pathology is designed to bring information of clinicopathologic significance to human disease to the laboratory and clinical physician. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to the understanding of human diseases. Papers published concern morphologic and clinicopathologic observations, reviews of diseases, analyses of problems in pathology, significant collections of case material and advances in concepts or techniques of value in the analysis and diagnosis of disease. Theoretical and experimental pathology and molecular biology pertinent to human disease are included. This critical journal is well illustrated with exceptional reproductions of photomicrographs and microscopic anatomy.